Pharming Group (PHGUF) Price & Analysis

Q: What was Pharming Group’s price range in the past 12 months?

Pharming Group lowest stock price was $0.74 and its highest was $1.85 in the past 12 months.

Q: What is Pharming Group’s market cap?

Pharming Group’s market cap is $1.13B.

Q: When is Pharming Group’s upcoming earnings report date?

Pharming Group’s upcoming earnings report date is Mar 12, 2026 which is in 79 days.

Q: How were Pharming Group’s earnings last quarter?

Pharming Group released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0 by $0.01.

Q: Is Pharming Group overvalued?

According to Wall Street analysts Pharming Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Pharming Group pay dividends?

Pharming Group does not currently pay dividends.

Q: What is Pharming Group’s EPS estimate?

Pharming Group’s EPS estimate is <0.01.

Q: How many shares outstanding does Pharming Group have?

Pharming Group has 685,147,640 shares outstanding.

Q: What happened to Pharming Group’s price movement after its last earnings report?

Pharming Group reported an EPS of $0.01 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 27.5%.

Q: Which hedge fund is a major shareholder of Pharming Group?

Currently, no hedge funds are holding shares in PHGUF

Compare

98 Followers

PHGUF Stock Chart & Stats

$1.70

-$0.03(-3.36%)

At close: Jan 06 4:00 PM EST

$1.70

-$0.03(-3.36%)

Day’s Range― - ―

52-Week Range$0.74 - $1.85

Previous CloseN/A

Volume1.00K

Average Volume (3M)580.00

Market Cap

$1.13B

Enterprise Value$821.05M

Total Cash (Recent Filing)$166.17M

Total Debt (Recent Filing)$130.92M

Price to Earnings (P/E)1133.3

Beta0.60

Next Earnings

Mar 12, 2026

EPS Estimate

<0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding685,147,640

10 Day Avg. Volume500

30 Day Avg. Volume580

Financial Highlights & Ratios

PEG Ratio-2.95

Price to Book (P/B)2.98

Price to Sales (P/S)2.22

P/FCF Ratio-255.48

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue2.27

Enterprise Value/Gross Profit2.52

Enterprise Value/Ebitda18.35

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Pharming Group News

Pharming price target raised to $42 from $41 at Oppenheimer

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $42 from $41 and keeps an Outperform rating...

2M ago

PHAR

Pharming Group Reports Strong Q3 2025 Growth

Pharming Group N.V. ( ($PHGUF) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

Pharming Group N.V. Reports Strong Q3 2025 Earnings

Pharming Group N.V. (($NL:PHARM)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

PHGUF Upcoming Earnings Report: What to Expect?

Pharming Group N.V. (PHGUF) is scheduled to report 3rd quarter earnings on 11/06/2025, before the market opens. Regarding...

2M ago

Pharming announces 20% net reduction in non-commercial, non-medical headcount

Pharming (PHAR) Group announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is...

3M ago

PHAR

Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group and keeping the price target...

3M ago

PHAR

= Pharming Group NV ADS trading resumes

12:06 EDT = Pharming (PHAR) Group NV ADS trading resumes Published first on TheFly – the ultimate source...

5M ago

PHAR

= Pharming Group NV ADS trading halted, volatility trading pause

11:41 EDT = Pharming (PHAR) Group NV ADS trading halted, volatility trading pause Published first on TheFly –...

5M ago

PHAR

Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital

RBC Capital raised the firm’s price target on Pharming (PHAR) to EUR 2.45 from EUR 2 and keeps...

5M ago

PHAR

Pharming Group N.V. Reports Strong Q2 Earnings

Pharming Group N.V. (($NL:PHARM)) has held its Q2 earnings call. Read on for the main highlights of the...

5M ago

Pharming price target raised to $41 from $40 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on Pharming (PHAR) to $41 from $40 and keeps...

5M ago

PHAR

Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with...

5M ago

PHAR

Pharming Group Reports Strong Revenue Growth in 2025

Pharming Group N.V. ( ($PHGUF) ) has released its Q2 earnings. Here is a breakdown of the information...

5M ago

Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment

Pharming Group (PHAR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

6M ago

PHAR

PHGUF FAQ

What was Pharming Group’s price range in the past 12 months?

Pharming Group lowest stock price was $0.74 and its highest was $1.85 in the past 12 months.

What is Pharming Group’s market cap?

Pharming Group’s market cap is $1.13B.

When is Pharming Group’s upcoming earnings report date?

Pharming Group’s upcoming earnings report date is Mar 12, 2026 which is in 79 days.

How were Pharming Group’s earnings last quarter?

Pharming Group released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0 by $0.01.

Is Pharming Group overvalued?

According to Wall Street analysts Pharming Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Pharming Group pay dividends?

Pharming Group does not currently pay dividends.

What is Pharming Group’s EPS estimate?

Pharming Group’s EPS estimate is <0.01.

How many shares outstanding does Pharming Group have?

Pharming Group has 685,147,640 shares outstanding.

What happened to Pharming Group’s price movement after its last earnings report?

Pharming Group reported an EPS of $0.01 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 27.5%.

Which hedge fund is a major shareholder of Pharming Group?

Currently, no hedge funds are holding shares in PHGUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Pharming Group (PHGUF) Earnings & Revenues

Historic Earnings Reports

PHGUF Company Deck

PHGUF Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.View all PHGUF earnings summaries